# A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

> **NCT06006559** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 108 (estimated)

## Conditions studied

- Dengue

## Interventions

- **DRUG:** EYU688
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06006559
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2027-01-07
- **Final completion:** 2027-01-15
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006559, "A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06006559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*